Evidence map›Paper›PMID 34181459›Full record

ArticleInfection and immunity2021

Surviving Serum: the Escherichia coli

Dvora Biran, Thomas Sura, Andreas Otto, Yael Yair, Dörte Becher, Eliora Z Ron

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Research Progress on perinatalFrontiers in microbiology · 2026
    Review
  8. Review
  9. Avian PathogenicVeterinary sciences · 2025
    Review
  10. Genomic Characterization ofMicroorganisms · 2025
    Article
  11. The role of bacterial metabolism in human gut colonization.International microbiology : the official journal of the Spanish Society for Microbiology · 2025
    Review
  12. Article
  13. Review
  14. Plasmid-Mediated Co-Occurrence ofTransboundary and emerging diseases · 2024
    Article
  15. Carbapenem-producingFrontiers in cellular and infection microbiology · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Genomic insights ofFrontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Dvora BiranThe Shmunis School of Biomedicine and Cancer Research, Faculty of Life Sciences, Tel Aviv Universitygrid.12136.37, Tel Aviv, Israel.
Thomas SuraInstitute for Microbiology, University of Greifswald, Greifswald, Germany.
Andreas OttoInstitute for Microbiology, University of Greifswald, Greifswald, Germany.
Yael YairThe Shmunis School of Biomedicine and Cancer Research, Faculty of Life Sciences, Tel Aviv Universitygrid.12136.37, Tel Aviv, Israel.
Dörte BecherInstitute for Microbiology, University of Greifswald, Greifswald, Germany.
Eliora Z RonThe Shmunis School of Biomedicine and Cancer Research, Faculty of Life Sciences, Tel Aviv Universitygrid.12136.37, Tel Aviv, Israel.ORCID 0000-0003-2615-8685
Tel Aviv University · ILUniversität Greifswald · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extraintestinal pathogenic Escherichia coli (ExPEC) strains constitute a serious and emerging clinical problem, as they cause a variety of infections and are usually highly antibiotic resistant. Many ExPEC strains are capable of evading the bactericidal effects of serum and causing sepsis. One critical factor for the development of septicemia is the increased serum survival (

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialEscherichia coli InfectionsEscherichia coli ProteinsExtraintestinal Pathogenic Escherichia coliHumansSepsisSerumAnti-Bacterial AgentsEscherichia coli ProteinsIss protein, E colicapsulecolisepticemiaextraintestinal pathogenic E. coli (ExPEC)group 4 capsuleincreased serum survival (Iss)O-antigen capsulesepsissepticemiaserum resistance

Identifiers

PMID34181459
PMCPMC8445191
OpenAlexW3174233863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.